primary antibodies against integrin β1  (Cell Signaling Technology Inc)

Journal: bioRxiv

Article Title: Integrin Activation Enhances Lesion-Specific Targeting of Monocyte-Mimetic Nanoparticles in Atherosclerosis

doi: 10.64898/2026.03.04.707824

Figure Lengend Snippet: Fluorescence images and quantification of nanoparticle uptake in TNFα-activated ECs under the following conditions: (A) VCAM1 blockade, (B) β1-integrin blockade on nanoparticles, and (C) CPZ treatment. Red: IA@MoNP, MoNP, or bare NP; blue: DAPI-stained nuclei. Scale bar = 50 μm. (A–B) *p < 0.05 vs. IgG antibody; # p < 0.05 vs. MoNP. (C) *p < 0.05 vs. control ECs; # p < 0.05 vs. bare NP. Data are presented as mean ± SD from n = 3 independent experiments.

Article Snippet: Membrane proteins were assessed by Western blot using antibodies against CD11b (Cell Signaling #17800, 1:1000), Na + /K + ATPase (Cell Signaling #3010, 1:1000), α4-integrin (Invitrogen #PA5-20599, 1:1000), and β1-integrin (Cell Signaling #4706S, 1:1000).

Techniques: Fluorescence, Staining, Control

Journal: bioRxiv

Article Title: Integrin Activation Enhances Lesion-Specific Targeting of Monocyte-Mimetic Nanoparticles in Atherosclerosis

doi: 10.64898/2026.03.04.707824

Figure Lengend Snippet: (A) Schematic illustration of the experimental design. (B) IVIS imaging and quantification of nanoparticle accumulation in partially ligated LCA of ApoE -/- mice. (C) Representative cross-sectional fluorescence images of the LCA. Red: IA@MoNP or MoNP; green: elastin fibers; blue: DAPI-stained nuclei. Scale bar = 100 μm. (D–E) IVIS analysis showing (D) biodistribution in major organs across nanoparticle formulations and (E) reduction of IA@MoNP signal in the LCA following β1-integrin blockade on nanoparticles. (B) *p < 0.05 vs. RCA; # p < 0.05 vs. MoNP; (E) *p < 0.05 vs. IgG antibody. Data are presented as mean ± SD from n = 4 mice each group.

Article Snippet: Membrane proteins were assessed by Western blot using antibodies against CD11b (Cell Signaling #17800, 1:1000), Na + /K + ATPase (Cell Signaling #3010, 1:1000), α4-integrin (Invitrogen #PA5-20599, 1:1000), and β1-integrin (Cell Signaling #4706S, 1:1000).

Techniques: Imaging, Fluorescence, Staining

Journal: Science Advances

Article Title: Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer

doi: 10.1126/sciadv.ady0041

Figure Lengend Snippet: ( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( ITGA3 and ITGB1 ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following siRNA knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.

Article Snippet: Plasmids encoding ITGA3 (pFUSEss- ITGA3 ), ITGB1 (Addgene no. 54129), or both were used to transfect at a 1:1 ratio using a total of 15 μg of DNA per 2 × 10 6 cells per plate.

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Flow Cytometry, Transfection, Knockdown, Recombinant

Journal: Science Advances

Article Title: Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer

doi: 10.1126/sciadv.ady0041

Figure Lengend Snippet: ( A ) ITGA3 mRNA expression in normal bladder tissues ( n = 18) and primary bladder tumors ( n = 408) based on TCGA data. ( B ) ITGA3 expression across consensus molecular subtypes of bladder cancer from five aggregated clinical cohorts. ( C ) Representative multiplex immunofluorescence images of TMA cores stained for ITGA3 (green), ITGB1 (red), and nuclei [DAPI (4′,6-diamidino-2-phenylindole), blue] of primary bladder carcinomas and normal tissues. Scale bars, 100 μm. ( D to F ) Quantification of ITGA3 expression in tumor versus normal tissues: fluorescence intensity (D), percentage of ITGA3 -positive cells (E), and H -scores (F). **** P < 0.0001.

Article Snippet: Plasmids encoding ITGA3 (pFUSEss- ITGA3 ), ITGB1 (Addgene no. 54129), or both were used to transfect at a 1:1 ratio using a total of 15 μg of DNA per 2 × 10 6 cells per plate.

Techniques: Expressing, Multiplex Assay, Immunofluorescence, Staining, Fluorescence